NATCO Pharma Statistics

Total Valuation

NATCO Pharma has a market cap or net worth of INR 156.74 billion. The enterprise value is 130.41 billion.

Market Cap	156.74B
Enterprise Value	130.41B

Important Dates

The last earnings date was Tuesday, May 27, 2025.

Earnings Date	May 27, 2025
Ex-Dividend Date	Feb 18, 2025

Share Statistics

Current Share Class	179.11M
Shares Outstanding	n/a
Shares Change (YoY)	-0.21%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	112.10M

Valuation Ratios

The trailing PE ratio is 8.31 and the forward PE ratio is 12.36.

PE Ratio	8.31
Forward PE	12.36
PS Ratio	3.54
PB Ratio	2.06
P/TBV Ratio	2.14
P/FCF Ratio	12.10
P/OCF Ratio	9.24
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.94, with an EV/FCF ratio of 10.07.

EV / Earnings	6.92
EV / Sales	2.94
EV / EBITDA	5.94
EV / EBIT	6.65
EV / FCF	10.07

Financial Position

The company has a current ratio of 5.59, with a Debt / Equity ratio of 0.04.

Current Ratio	5.59
Quick Ratio	3.97
Debt / Equity	0.04
Debt / EBITDA	0.13
Debt / FCF	0.22
Interest Coverage	82.04

Financial Efficiency

Return on equity (ROE) is 27.97% and return on invested capital (ROIC) is 17.34%.

Return on Equity (ROE)	27.97%
Return on Assets (ROA)	15.78%
Return on Invested Capital (ROIC)	17.34%
Return on Capital Employed (ROCE)	25.51%
Revenue Per Employee	11.03M
Profits Per Employee	4.69M
Employee Count	4,016
Asset Turnover	0.57
Inventory Turnover	0.89

Taxes

In the past 12 months, NATCO Pharma has paid 4.08 billion in taxes.

Income Tax	4.08B
Effective Tax Rate	17.81%

Stock Price Statistics

The stock price has decreased by -25.31% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.31%
50-Day Moving Average	855.41
200-Day Moving Average	1,150.29
Relative Strength Index (RSI)	49.92
Average Volume (20 Days)	72,095

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NATCO Pharma had revenue of INR 44.30 billion and earned 18.85 billion in profits. Earnings per share was 105.26.

Revenue	44.30B
Gross Profit	37.40B
Operating Income	19.61B
Pretax Income	22.91B
Net Income	18.85B
EBITDA	21.96B
EBIT	19.61B
Earnings Per Share (EPS)	105.26

Full Income Statement

Balance Sheet

The company has 24.97 billion in cash and 2.79 billion in debt, giving a net cash position of 22.17 billion.

Cash & Cash Equivalents	24.97B
Total Debt	2.79B
Net Cash	22.17B
Net Cash Per Share	n/a
Equity (Book Value)	76.12B
Book Value Per Share	424.69
Working Capital	43.27B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 16.97 billion and capital expenditures -4.01 billion, giving a free cash flow of 12.96 billion.

Operating Cash Flow	16.97B
Capital Expenditures	-4.01B
Free Cash Flow	12.96B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 84.43%, with operating and profit margins of 44.27% and 42.56%.

Gross Margin	84.43%
Operating Margin	44.27%
Pretax Margin	51.73%
Profit Margin	42.56%
EBITDA Margin	49.58%
EBIT Margin	44.27%
FCF Margin	29.25%

Dividends & Yields

This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 0.69%.

Dividend Per Share	6.00
Dividend Yield	0.69%
Dividend Growth (YoY)	-36.84%
Years of Dividend Growth	n/a
Payout Ratio	5.72%
Buyback Yield	0.21%
Shareholder Yield	0.90%
Earnings Yield	12.03%
FCF Yield	8.27%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.

Last Split Date	Nov 26, 2015
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	5